Differential Diagnosis of Spontaneous Pneumothorax

Total Page:16

File Type:pdf, Size:1020Kb

Differential Diagnosis of Spontaneous Pneumothorax Appendix 2: Causes of spontaneous pneumothorax.1–3 Clinical and Chest imaging demographic (excluding findings Pulmonary function Genetics Cause features of pneumothorax) tests (Mendelian) Special tests Primary Typically seen in Usually normal Usually normal Not applicable None, but spontaneous men during early thoracoscopy pneumothorax adulthood; patients performed for are usually tall and therapeutic reasons thin; strongly often shows associated with a subpleural blebs history of smoking COPD Prevalence May be normal in Airflow obstruction Not applicable None increases with age early disease; that is not fully (see separate from mid-adulthood findings in more reversible, often discussion of alpha on; strongly advanced disease with a decrease in 1-antitrypsin associated with a include diffusing capacity deficiency, below, history of smoking hyperinflation, which accounts for vascular deficiency, ~1-2% of cases of centrilobular COPD) emphysema, and bullae; classically upper lung- predominant Alpha 1-antitrypsin Development of May be normal in May be normal; Autosomal Alpha 1-antitrypsin deficiency early-onset (age early disease; airflow obstruction recessive level < 20 µmol/L; 30–40) and (or) findings in more that is not fully protease inhibitor severe emphysema advanced disease reversible, often protein phenotyping (including include with a decrease in emphysema that is hyperinflation, diffusing capacity not in proportion to vascular deficiency, history of smoking); panacinar possible emphysema and bronchiectasis and bullae; classically extrapulmonary lower lung- involvement (e.g., predominant liver disease) Asthma Development of Usually normal May be normal; Not applicable Bronchial paroxysmal or variable airflow hyperresponsiveness persistent airway obstruction, often challenges, allergy disorder with with a normal testing variable clinical diffusing capacity phenotype and age of onset; possible features of atopy Cystic fibrosis Bronchiectasis with Hyperinflation, Airflow obstruction Autosomal Sweat chloride level, bacterial upper lung- that is not fully recessive CFTR gene testing colonization, mostly predominant reversible, often commonly findings of with a decrease in beginning in bronchiectasis (eg. diffusing capacity childhood; frequent bronchial wall extrapulmonary thickening, mucous involvement (e.g., plugging, ring rhinosinusitis and shadows, tram lines, nasal polyps, cysts) exocrine and endocrine pancreatic disease, infertility) Appendix to: Pierce CW, Hull PR, Lemire EG, Marciniuk D. Birt–Hogg–Dubé syndrome: an inherited cause of spontaneous pneumothorax. CMAJ 2011. DOI:10.1503/cmaj.092121. Copyright © 2011, Canadian Medical Association or its licensors Appendix 2 continued Clinical and Chest imaging demographic (excluding findings Pulmonary function Genetics Cause features of pneumothorax) tests (Mendelian) Special tests Sequelae of Development of Variable, depending Not applicable Not applicable Dependent on pulmonary infection cystic and (or) on cause and clinical cavitary lesions on pathogen circumstances the basis of necrotizing pneumonia, TB, septic emboli, Pneumocystis infection LAM Pulmonary lesions, May be normal in May be normal, Not applicable; Consistent clinical almost exclusively in early disease; obstructive, associated tuberous and CT findings women of findings in more restrictive, or mixed, sclerosis is may suffice for childbearing age; advanced disease often with a autosomal dominant diagnosis; surgical also found in up to include decrease in lung biopsy is 40% of women with reticulonodular diffusing capacity. definitive TS (most infiltrates, cysts, (bronchoscopic prominently bullae, and pleural testing often dermatologic and effusion; lung nondiagnostic); neurologic volumes may be tuberous sclerosis is abnormalities); normal or increased diagnosed clinically, extrapulmonary and testing of TSC1 involvement and TSC2 loci is common (e.g., renal available angiomyolipomas) Pulmonary Development of Usually upper lung- May be normal, Not applicable Surgical lung biopsy Langerhans’ cell pulmonary lesions, predominant obstructive, (bronchoscopic histiocytosis (PLCH) in young adulthood reticulonodular restrictive, or mixed, testing often (e.g., age 20–30 infiltrate, cavitating often with a nondiagnostic) years); very strongly nodules, and cysts; decrease in associated with lung volumes may diffusing capacity. current and heavy be normal or smoking; occasional increased extrapulmonary involvement (e.g., bone lesions, diabetes insipidus) Birt–Hogg–Dubé Development of skin Chest radiograph Usually normal Autosomal dominant FLCN gene testing syndrome lesions, renal may be normal, is available tumours and chest CT may show pulmonary cysts cysts Appendix to: Pierce CW, Hull PR, Lemire EG, Marciniuk D. Birt–Hogg–Dubé syndrome: an inherited cause of spontaneous pneumothorax. CMAJ 2011. DOI:10.1503/cmaj.092121. Copyright © 2011, Canadian Medical Association or its licensors Appendix 2 concluded Clinical and Chest imaging demographic (excluding findings Pulmonary function Genetics Cause features of pneumothorax) tests (Mendelian) Special tests Marfan syndrome Musculoskeletal Usually normal; may Usually normal Autosomal dominant echocardiogram, slit abnormalities (e.g., show features of lamp examination; tall stature, long underlying chest FBN1 gene testing limbs, wall or is available arachynodactyly, cardiovascular chest wall lesions deformity), cardiovascular lesions (e.g., ascending aortic aneurysm and dissection, mitral valve prolapse), and ocular lesions (e.g., lens dislocation, myopia) Ehlers–Danlos Characterized by Usually normal Usually normal Autosomal dominant Biochemical testing syndrome (type IV: thin/translucent skin, of type III vascular type) easy bruising, procollagen in characteristic facial fibroblasts, COL3A1 appearance, as well gene testing as arterial and visceral rupture Note: CT = computed tomography, COL3A1 = collagen type III alpha 1, COPD = chronic obstructive pulmonary disease, FBN1 = fibrillin 1 , FLCN = folliculin, LAM = lymphangioleiomyomatosis, TS = tuberous sclerosis, TSC1 = tuberous sclerosis 1, TSC2 = tuberous sclerosis 2. References 1. Kasper DL, Braunwald E, Fauci AS, et al. Harrison’s principles of internal medicine. 17th ed. New York (NY): McGraw- Hill Medical Publishing Division; 2008. p. 1635-40, p. 1648-50, p. 1660, p. 2465-69. 2. Mason RJ, Broaddus VC, Martin TR, et al. Murray and Nadel’s textbook of respiratory medicine. 5th ed. Philadelphia (PA): Saunders Elsevier; 2010. p. 883-902, p. 941-3, p. 985-1005, p. 1496-1507, p. 1766-70. 3. GeneReviews. GeneTests: Medical Genetics Information Resource [database]. Seattle (USA): University of Washington, Seattle; 1993–2010. Available: www.genetests.org (accessed 2010 Oct. 6) Appendix to: Pierce CW, Hull PR, Lemire EG, Marciniuk D. Birt–Hogg–Dubé syndrome: an inherited cause of spontaneous pneumothorax. CMAJ 2011. DOI:10.1503/cmaj.092121. Copyright © 2011, Canadian Medical Association or its licensors .
Recommended publications
  • Spontaneous Pneumothorax in COVID-19 Patients Treated with High-Flow Nasal Cannula Outside the ICU: a Case Series
    International Journal of Environmental Research and Public Health Case Report Spontaneous Pneumothorax in COVID-19 Patients Treated with High-Flow Nasal Cannula outside the ICU: A Case Series Magdalena Nalewajska 1, Wiktoria Feret 1 , Łukasz Wojczy ´nski 1, Wojciech Witkiewicz 2 , Magda Wi´sniewska 1 and Katarzyna Kotfis 3,* 1 Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70–111 Szczecin, Poland; [email protected] (M.N.); [email protected] (W.F.); [email protected] (Ł.W.); [email protected] (M.W.) 2 Department of Cardiology, Pomeranian Medical University, 70–111 Szczecin, Poland; [email protected] 3 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70–111 Szczecin, Poland * Correspondence: katarzyna.kotfi[email protected] Abstract: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic and a burden to global health at the turn of 2019 and 2020. No targeted treatment for COVID-19 infection has been identified so far, thus supportive treatment, invasive and non-invasive oxygen support, and corticosteroids remain a common therapy. High-flow nasal cannula (HFNC), a non-invasive oxygen support method, has become a prominent treatment option for respiratory failure during the SARS-CoV-2 pandemic. Citation: Nalewajska, M.; Feret, W.; HFNC reduces the anatomic dead space and increases positive end-expiratory pressure (PEEP), Wojczy´nski,Ł.; Witkiewicz, W.; allowing higher concentrations and higher flow of oxygen. Some studies suggest positive effects of Wi´sniewska,M.; Kotfis, K. HFNC on mortality and avoidance of intubation.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation
    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation Dr Rohit Bazaz National Aspergillosis Centre, UK Manchester University NHS Foundation Trust/University of Manchester ~ ABPA -a41'1 Severe asthma wl'th funga I Siens itisat i on Subacute IA Chronic pulmonary aspergillosjs Simp 1Ie a:spe rgmoma As r§i · bronchitis I ram une dysfu net Ion Lun· damage Immu11e hypce ractivitv Figure 1 In t@rarctfo n of Aspergillus Vliith host. ABP A, aHerg tc broncho pu~ mo na my as µe rgi ~fos lis; IA, i nvas we as ?@rgiH os 5. MANCHl·.'>I ER J:-\2 I Kosmidis, Denning . Thorax 2015;70:270–277. doi:10.1136/thoraxjnl-2014-206291 Allergic Fungal Airway Disease Phenotypes I[ Asthma AAFS SAFS ABPA-S AAFS-asthma associated with fu ngaIsensitization SAFS-severe asthma with funga l sensitization ABPA-S-seropositive a llergic bronchopulmonary aspergi ll osis AB PA-CB-all ergic bronchopulmonary aspergi ll osis with central bronchiectasis Agarwal R, CurrAlfergy Asthma Rep 2011;11:403 Woolnough K et a l, Curr Opin Pulm Med 2015;21:39 9 Stanford Lucile Packard ~ Children's. Health Children's. Hospital CJ Scanford l MEDICINE Stanford MANCHl·.'>I ER J:-\2 I Aspergi 11 us Sensitisation • Skin testing/specific lgE • Surface hydroph,obins - RodA • 30% of patients with asthma • 13% p.atients with COPD • 65% patients with CF MANCHl·.'>I ER J:-\2 I Alternar1a• ABPA •· .ABPA is an exagg·erated response ofthe imm1une system1 to AspergUlus • Com1pUcatio n of asthm1a and cystic f ibrosis (rarell·y TH2 driven COPD o r no identif ied p1 rior resp1 iratory d isease) • ABPA as a comp1 Ucation of asth ma affects around 2.5% of adullts.
    [Show full text]
  • To Honeycombing in Idiopathic Pulmonary Fibrosis
    Piciucchi et al. BMC Pulmonary Medicine (2016) 16:87 DOI 10.1186/s12890-016-0245-x CORRESPONDENCE Open Access From “traction bronchiectasis” to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology? Sara Piciucchi1*, Sara Tomassetti2, Claudia Ravaglia2, Christian Gurioli2, Carlo Gurioli2, Alessandra Dubini3, Angelo Carloni4, Marco Chilosi5, Thomas V Colby6 and Venerino Poletti2,7 Abstract Background: The diagnostic and prognostic impact of traction bronchiectasis on high resolution CT scan (HRCT) in patients suspected to have idiopathic pulmonary fibrosis (IPF) is increasing significantly. Main body: Recent data demonstrated that cysts in honeycombing areas are covered by epithelium expressing bronchiolar markers. In IPF bronchiolization is the final consequence of a variety of pathogenic events starting from alveolar stem cell exhaustion, and ending in a abnormal/dysplastic proliferation of bronchiolar epithelium. CT scan features of traction bronchiectasis and honeycombing should be interpreted under the light of these new pathogenetic and morphologic considerations. Short conclusion: We suggest that in IPF subjects traction bronchiectasis and honeycombing -now defined as distinct entities on HRCT scan- are actually diverse aspects of a continuous spectrum of lung remodeling. Keywords: Traction bronchiectasis, Honeycombing, Fibroblastic Foci, Bronchiolar dysplastic proliferation Background Mechanical stress may contribute to the subpleural Histologically, Usual Interstitial Pneumonia (UIP) is and usually basilar localization of UIP changes [10, 11]. characterized by a combination of “patchy fibrosis” and The final stage of this “bronchiolization” process cor- fibroblastic foci displaying a “patchwork pattern”. Disease responds radiologically to honeycombing, typically seen progression is characterized by the appearance of air- first in the subpleural regions of the lower lobes [2, 3].
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis: a Perplexing Clinical Entity Ashok Shah,1* Chandramani Panjabi2
    Review Allergy Asthma Immunol Res. 2016 July;8(4):282-297. http://dx.doi.org/10.4168/aair.2016.8.4.282 pISSN 2092-7355 • eISSN 2092-7363 Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity Ashok Shah,1* Chandramani Panjabi2 1Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India 2Department of Respiratory Medicine, Mata Chanan Devi Hospital, New Delhi, India This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. In susceptible individuals, inhalation of Aspergillus spores can affect the respiratory tract in many ways. These spores get trapped in the viscid spu- tum of asthmatic subjects which triggers a cascade of inflammatory reactions that can result in Aspergillus-induced asthma, allergic bronchopulmo- nary aspergillosis (ABPA), and allergic Aspergillus sinusitis (AAS). An immunologically mediated disease, ABPA, occurs predominantly in patients with asthma and cystic fibrosis (CF). A set of criteria, which is still evolving, is required for diagnosis. Imaging plays a compelling role in the diagno- sis and monitoring of the disease. Demonstration of central bronchiectasis with normal tapering bronchi is still considered pathognomonic in pa- tients without CF. Elevated serum IgE levels and Aspergillus-specific IgE and/or IgG are also vital for the diagnosis. Mucoid impaction occurring in the paranasal sinuses results in AAS, which also requires a set of diagnostic criteria. Demonstration of fungal elements in sinus material is the hall- mark of AAS.
    [Show full text]
  • Klebsiella Pneumoniae in Diffuse Panbronchiolitis
    ※ 附來的圖四解析度和原來一樣哦 , 應該不是原始檔案 , 如沒有原圖印刷就是字不漂亮 DOI:10.6314/JIMT.202012_31(6).07 內科學誌 2020:31:432-436 Klebsiella Pneumoniae in Diffuse Panbronchiolitis Hwee-Kheng Lim1, Sho-Ting Hung2, and Shih-Yi Lee3,4 1Division of Infectious Diseases, Department of Medicine, 2Department of Radiology, 3Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Taitung MacKay Memorial Hospital, Taitung, Taiwan; 4MacKay Medicine, Nursing & Management College Abstract Diffuse panbronchiolitis (DPB) is a chronic, idiopathic, rare but lethal inflammatory airway disease resulting in distal airway dilation, obstructive lung disease, hypoxemia, and increased in the susceptibility of bacteria colonization. The case reports that a patient with destructive lung gets pneumonia by Klebsiella pneu- moniae cured by bactericidal antibiotics, but K. pneumoniae in the airway is eradicated with erythromycin, which therefore highlights not only the importance to the testing for DPB in suspicious patients, but also the therapeutic strategies in managing DPB with K. pneumoniae in the airways. (J Intern Med Taiwan 2020; 31: 432-436) Key Words: Klebsiella pneumoniae, Panbronchiolitis Introduction the survival of the patients with DPB in the literature also reduces P. aeruginosa isolated from the sputum. Diffuse panbronchiolitis (DPB) is a chronic P. aeruginosa in sputum appears to accelerate the inflammatory disease of the airways, and the diag- destructive process3. However, the role of Klebsiella nosis depends on the clinical symptoms, physical pneumoniae in DPB has never been reported. We signs, typical chest radiographic findings, low FEV1 present a patient with DPB and K. pneumoniae iso- (< 70%) in pulmonary function tests, low arterial lated from sputum, refractory to ampicillin/sulbac- partial pressure (< 80 mmHg), elevated cold hem- tam, but eradicated by erythromycin.
    [Show full text]
  • Pneumothorax in Patients with Idiopathic Pulmonary Fibrosis
    Yamazaki et al. BMC Pulm Med (2021) 21:5 https://doi.org/10.1186/s12890-020-01370-w RESEARCH ARTICLE Open Access Pneumothorax in patients with idiopathic pulmonary fbrosis: a real-world experience Ryo Yamazaki, Osamu Nishiyama* , Kyuya Gose, Sho Saeki, Hiroyuki Sano, Takashi Iwanaga and Yuji Tohda Abstract Background: Some patients with idiopathic pulmonary fbrosis (IPF) develop pneumothorax. However, the charac- teristics of pneumothorax in patients with IPF have not been elucidated. The purpose of this study was to clarify the clinical course, actual management, and treatment outcomes of pneumothorax in patients with IPF. Methods: Consecutive patients with IPF who were admitted for pneumothorax between January 2008 and Decem- ber 2018 were included. The success rates of treatment for pneumothorax, hospital mortality, and recurrence rate after discharge were examined. Results: During the study period, 36 patients with IPF were admitted with pneumothorax a total of 58 times. During the frst admission, 15 patients (41.7%) did not receive chest tube drainage, but 21 (58.3%) did. Of the 21 patients, 8 (38.1%) received additional therapy after chest drainage. The respective treatment success rates were 86.6% and 66.7% in patients who underwent observation only vs chest tube drainage. The respective hospital mortality rates were 13.3% and 38.0%. The total pneumothorax recurrence rate after hospital discharge was 34.6% (n 9). = Conclusions: Pneumothorax in patients with IPF was difcult to treat successfully, had a relatively poor prognosis, and showed a high recurrence rate. Keywords: Idiopathic pulmonary fbrosis, Hospitalization, Pneumothorax, Recurrence, Treatment Background pneumothorax was signifcantly associated with poor Idiopathic pulmonary fbrosis (IPF) is a specifc form survival in patients with IPF [11].
    [Show full text]
  • Secondary Spontaneous Pneumothorax in a Patient of Allergic Bronchopulmonary Aspergillosis: an Unusual Presentation
    International Journal of Research in Medical Sciences Sandal S et al. Int J Res Med Sci. 2021 Apr;9(4):1205-1208 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20211377 Case Report Secondary spontaneous pneumothorax in a patient of allergic bronchopulmonary aspergillosis: an unusual presentation Shivali Sandal1, Surender Kumar2* 1Department of Critical Care Medicine, Inderaprastha Apollo, New Delhi, India 2Department of Cardiology, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India Received: 23 January 2021 Accepted: 01 March 2021 *Correspondence: Dr. Surender Kumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Allergic bronchopulmonary aspergillosis (ABPA) is a complex immunologic pulmonary disorder caused by hypersensitivity to fungus, Aspergillus fumigates. It clinically manifests with non-specific respiratory and systemic symptoms. ABPA is typically seen in patients with long-standing asthma or cystic fibrosis. Pleural involvement in ABPA is uncommon and secondary spontaneous pneumothorax is very rare. Herein, we report a case of 33 years old male patient presented with dyspnoea, low grade fever and productive cough. High Resolution Computed tomography (HRCT) scan of thorax was suggestive of ABPA with secondary pneumothorax. Keywords: Allergic bronchopulmonary aspergillosis, Aspergillus fumigates, High resolution computed tomography, Secondary spontaneous pneumothorax INTRODUCTION episodes of increasing dyspnea, cough with sputum production, pleuritic pain and fever.
    [Show full text]
  • IDSA/ATS Consensus Guidelines on The
    SUPPLEMENT ARTICLE Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults Lionel A. Mandell,1,a Richard G. Wunderink,2,a Antonio Anzueto,3,4 John G. Bartlett,7 G. Douglas Campbell,8 Nathan C. Dean,9,10 Scott F. Dowell,11 Thomas M. File, Jr.12,13 Daniel M. Musher,5,6 Michael S. Niederman,14,15 Antonio Torres,16 and Cynthia G. Whitney11 1McMaster University Medical School, Hamilton, Ontario, Canada; 2Northwestern University Feinberg School of Medicine, Chicago, Illinois; 3University of Texas Health Science Center and 4South Texas Veterans Health Care System, San Antonio, and 5Michael E. DeBakey Veterans Affairs Medical Center and 6Baylor College of Medicine, Houston, Texas; 7Johns Hopkins University School of Medicine, Baltimore, Maryland; 8Division of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi School of Medicine, Jackson; 9Division of Pulmonary and Critical Care Medicine, LDS Hospital, and 10University of Utah, Salt Lake City, Utah; 11Centers for Disease Control and Prevention, Atlanta, Georgia; 12Northeastern Ohio Universities College of Medicine, Rootstown, and 13Summa Health System, Akron, Ohio; 14State University of New York at Stony Brook, Stony Brook, and 15Department of Medicine, Winthrop University Hospital, Mineola, New York; and 16Cap de Servei de Pneumologia i Alle`rgia Respirato`ria, Institut Clı´nic del To`rax, Hospital Clı´nic de Barcelona, Facultat de Medicina, Universitat de Barcelona, Institut d’Investigacions Biome`diques August Pi i Sunyer, CIBER CB06/06/0028, Barcelona, Spain. EXECUTIVE SUMMARY priate starting point for consultation by specialists. Substantial overlap exists among the patients whom Improving the care of adult patients with community- these guidelines address and those discussed in the re- acquired pneumonia (CAP) has been the focus of many cently published guidelines for health care–associated different organizations, and several have developed pneumonia (HCAP).
    [Show full text]
  • Community Acquired Pneumonia Sonia Akter*, Shamsuzzaman and Ferdush Jahan
    Akter et al. Int J Respir Pulm Med 2015, 2:1 International Journal of ISSN: 2378-3516 Respiratory and Pulmonary Medicine Review Article : Open Access Community Acquired Pneumonia Sonia Akter*, Shamsuzzaman and Ferdush Jahan Department of Microbiology, Dhaka Medical College, Bangladesh *Corresponding author: Sonia Akter, Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh, E-mail: [email protected] or residing in a long term care facility for > 14 days before the onset Abstract of symptoms [4]. Diagnosis depends on isolation of the infective Community-acquired pneumonia (CAP) is typically caused by organism from sputum and blood. Knowledge of predominant an infection but there are a number of other causes. The most microbial patterns in CAP constitutes the basis for initial decisions common type of infectious agents is bacteria such as Streptococcus about empirical antimicrobial treatment [5]. pneumonia. CAP is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the Microbial Pathogens community. CAP remains a common and potentially serious illness. It is associated with considerable morbidity, mortality and treatment Strep. pneumoniae accounted for over 80 percent of cases of cost, particularly in elderly patients. CAP causes problems like community-acquired pneumonia in the era before penicillin [6]. difficulty in breathing, fever, chest pains, and cough. Definitive Strep. pneumoniae is still the single most common defined pathogen clinical diagnosis should be based on X-ray finding and culture in nearly all studies of hospitalized adults with community-acquired of lung aspirates. The chest radiograph is considered the” gold pneumonia [7-9]. Other bacteria commonly encountered in cultures of standard” for the diagnosis of pneumonia but cannot differentiate bacterial from non bacterial pneumonia.
    [Show full text]
  • Cryptogenic Organizing Pneumonia
    462 Cryptogenic Organizing Pneumonia Vincent Cottin, M.D., Ph.D. 1 Jean-François Cordier, M.D. 1 1 Hospices Civils de Lyon, Louis Pradel Hospital, National Reference Address for correspondence and reprint requests Vincent Cottin, Centre for Rare Pulmonary Diseases, Competence Centre for M.D., Ph.D., Hôpital Louis Pradel, 28 avenue Doyen Lépine, F-69677 Pulmonary Hypertension, Department of Respiratory Medicine, Lyon Cedex, France (e-mail: [email protected]). University Claude Bernard Lyon I, University of Lyon, Lyon, France Semin Respir Crit Care Med 2012;33:462–475. Abstract Organizing pneumonia (OP) is a pathological pattern defined by the characteristic presence of buds of granulation tissue within the lumen of distal pulmonary airspaces consisting of fibroblasts and myofibroblasts intermixed with loose connective matrix. This pattern is the hallmark of a clinical pathological entity, namely cryptogenic organizing pneumonia (COP) when no cause or etiologic context is found. The process of intraalveolar organization results from a sequence of alveolar injury, alveolar deposition of fibrin, and colonization of fibrin with proliferating fibroblasts. A tremen- dous challenge for research is represented by the analysis of features that differentiate the reversible process of OP from that of fibroblastic foci driving irreversible fibrosis in usual interstitial pneumonia because they may determine the different outcomes of COP and idiopathic pulmonary fibrosis (IPF), respectively. Three main imaging patterns of COP have been described: (1) multiple patchy alveolar opacities (typical pattern), (2) solitary focal nodule or mass (focal pattern), and (3) diffuse infiltrative opacities, although several other uncommon patterns have been reported, especially the reversed halo sign (atoll sign).
    [Show full text]
  • Treating Bronchiectasis
    American Thoracic Society PATIENT EDUCATION | INFORMATION SERIES Treating Bronchiectasis Bronchiectasis (bron-kee-eck-tuh-sis) is a lung condition that causes cough, sputum production, and recurrent respiratory infections. (Also see “What is Bronchiectasis?” at www.thoracic.org/patients). Because bronchiectasis is a condition that develops over many years and worsens with repeated infections, the main treatment goal is to reduce stagnant secretions (mucus, sputum) in the airways and germs contained in those secretions. Your healthcare provider will help you figure out the ■ chest physiotherapy involves chest clapping in best treatment plan for you. There are two important various positions to move mucus up to the windpipe parts of bronchiectasis treatment: so that you can cough it out. ■ Maintenance: What you do every day. This usually ■ handheld positive expiratory pressure (PEP) devices includes airway clearance, changes in your lifestyle, are used to loosen mucus by creating vibration while and other actions you can take to prevent infections and lung damage. breathing through the device. ■ Exacerbations (eg-zass-er-bay-shuns): What you do ■ percussion devices which can include mechanical when you get sick and have a change in symptoms. percussors and percussive vests (high frequency This usually includes increasing airway clearance and chest wall oscilliation) are used to loosen mucus and CLIP AND COPY AND CLIP taking antibiotics to treat infection. move it to the windpipe to cough out. What are airway clearance techniques? All forms of airway clearance depend on good coughs Depending on how severe your bronchiectasis is and how much mucus is produced in your airways, your to move loose mucus out.
    [Show full text]
  • Concurrent Allergic Bronchopulmonary Aspergillosis and Aspergilloma: Is It a More Severe Form of the Disease?
    Eur Respir Rev 2010; 19: 118, 261–263 DOI: 10.1183/09059180.00009010 CopyrightßERS 2010 EDITORIAL Concurrent allergic bronchopulmonary aspergillosis and aspergilloma: is it a more severe form of the disease? A. Shah he mould Aspergillus, a genus of spore forming fungi, lung diseases in which aspergilloma formation has been affects the respiratory system in more ways than one. reported include sarcoidosis [15], hydatidosis [16], pneumato- T The clinical spectrum of Aspergillus involvement of the coele caused by Pneumocystis pneumonia [17], bronchiectasis, lungs ranges from various hypersensitivity manifestations to emphysematous bullae, and sites of prior lobectomies or invasive disease which can be fatal. The inhaled spores hardly pneumonectomies. The time required for the development of affect healthy persons but in asthmatic subjects these spores fungal balls ranges from a few months to more than 10 yrs [18]. are trapped in the viscid secretions found in the airways. Repeated inhalation of Aspergillus antigens triggers allergic The clinical categories of Aspergillus-related respiratory disor- reactions in atopic individuals, which may manifest as ders, for reasons unknown, usually remain mutually exclusive. Aspergillus-induced asthma, allergic bronchopulmonary asper- In spite of similar immunopathological responses, concomitant gillosis (ABPA) and allergic Aspergillus sinusitis (AAS) [1]. occurrence of ABPA and AAS is infrequently reported [19–22]. Saprobic colonisation of airways, cavities and necrotic tissue In this issue of the European Respiratory Review,MONTANI et al. leads to the development of aspergillomas. [23] describe a 50-yr-old female with concomitant ABPA and aspergilloma. Even though chronic lung damage appears to Although ABPA is predominantly a disease of asthmatics, only provide a favourable milieu for aspergilloma formation, the a few asthmatics actually suffer from it.
    [Show full text]